Pharmacology and Therapeutics

  1. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID‐19

    1. Virginia D. Schmith
    2. Jie (Jessie) Zhou
    3. Lauren R.L. Lohmer

    Reviewed by ScreenIT

    2 evaluationsAppears in 1 listLatest version Latest activity

  2. Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies

    1. James A. Watson
    2. Stephen M. Kissler
    3. Nicholas P. J. Day
    4. Yonatan H. Grad
    5. Nicholas J. White

    Reviewed by ScreenIT

    2 evaluationsAppears in 1 listLatest version Latest activity

  3. Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19

    1. Sara Schumann
    2. Astrid Kaiser
    3. Ferdinando Nicoletti
    4. Katia Mangano
    5. Paolo Fagone
    6. Eduard van Wijk
    7. Yu Yan
    8. Petra Schulz
    9. Beate Ludescher
    10. Michael Niedermaier
    11. Joerg von Wegerer
    12. Pia Rauch
    13. Christian Setz
    14. Ulrich Schubert
    15. Wolfgang Brysch

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  4. IN-HOSPITAL CONTINUATION WITH ANGIOTENSIN RECEPTOR BLOCKERS IS ASSOCIATED WITH A LOWER MORTALITY RATE THAN CONTINUATION WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN COVID-19 PATIENTS: A RETROSPECTIVE COHORT STUDY

    1. Francisco J. de Abajo
    2. Antonio Rodríguez-Miguel
    3. Sara Rodríguez-Martín
    4. Victoria Lerma
    5. Alberto García-Lledó

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  5. Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial

    1. Leticia R. Cruz
    2. Idania Baladrón
    3. Aliusha Rittoles
    4. Pablo A. Díaz
    5. Carmen Valenzuela
    6. Raúl Santana
    7. Maria M. Vázquez
    8. Ariadna García
    9. Deyli Chacón
    10. Delvin Thompson
    11. Gustavo Perera
    12. Ariel González
    13. Rafael Reyes
    14. Loida Torres
    15. Jesus Pérez
    16. Yania Valido
    17. Ralysmay Rodriguez
    18. Dania M. Vázquez-Bloomquist
    19. Mauro Rosales
    20. Ailyn C. Ramón
    21. George V. Pérez
    22. Gerardo Guillén
    23. Verena Muzio
    24. Yasser Perera
    25. Silvio E. Perea
    26. ATENEA-Co-300 Group

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  6. Network reinforcement driven drug repurposing for COVID-19 by exploiting disease-gene-drug associations

    1. Yonghyun Nam
    2. Jae-Seung Yun
    3. Seung Mi Lee
    4. Ji Won Park
    5. Ziqi Chen
    6. Brian Lee
    7. Anurag Verma
    8. Xia Ning
    9. Li Shen
    10. Dokyoon Kim

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  7. Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach

    1. Riffat Mehboob
    2. Fridoon Jawad Ahmad
    3. Ahad Qayyum
    4. Muhammad Asim Rana
    5. Syed Amir Gilani
    6. Muhammad Akram Tariq
    7. Javed Akram

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  8. Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series

    1. Marc-Antoine Lepage
    2. Nicholas Rozza
    3. Richard Kremer
    4. Ami Grunbaum

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  9. Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France

    1. Emilie Sbidian
    2. Julie Josse
    3. Guillaume Lemaitre
    4. Imke Meyer
    5. Mélodie Bernaux
    6. Alexandre Gramfort
    7. Nathanaël Lapidus
    8. Nicolas Paris
    9. Antoine Neuraz
    10. Ivan Lerner
    11. Nicolas Garcelon
    12. Bastien Rance
    13. Olivier Grisel
    14. Thomas Moreau
    15. Ali Bellamine
    16. Pierre Wolkenstein
    17. Gaël Varoquaux
    18. Eric Caumes
    19. Marc Lavielle
    20. Armand Mekontso Dessap
    21. Etienne Audureau
    22. AP-HP Covid CDR Initiative and ‘Entrepôt de Données de Santé’ AP-HP consortium

    Reviewed by ScreenIT

    2 evaluationsAppears in 1 listLatest version Latest activity

  10. Fluoxetine pharmacokinetics and tissue distribution suggest a possible role in reducing SARS-CoV-2 titers

    1. Andy R. Eugene

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity
Previous Page 7 of 8 Next